Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Ipsen has executed 8 deals since 2017, with a sharp pivot toward hematology driving its most recent — and largest — transactions. Here's what their deal activity tells BD teams, founders, and investors about where Ipsen is heading and how to position assets accordingly.
AbbVie executed 59 deals between late 2023 and mid-2026, committing over $30B in total deal value across co-development, licensing, and acquisitions. The pattern is unmistakable: AbbVie is rebuilding its immunology moat while quietly assembling a next-generation oncology pipeline.
The median upfront payment for a Phase 2 monoclonal antibody neurology acquisition now sits at $284M — but the five largest recent deals in this space all closed with $0 upfront. That paradox tells you everything about how neurology M&A actually works, and why standard benchmarks mislead both buyers and sellers.
The median upfront payment for a Phase 2 small molecule oncology acquisition just hit $284M — and the total deal values are pushing past $3.9B. We break down exactly what's driving these numbers, deconstruct the biggest comparable deals of 2025, and provide the negotiation playbook your deal team actually needs.
The median upfront for an ASO women's health acquisition at Phase 2 is $284M — but the spread between floor and ceiling is over $600M. This analysis breaks down why, deconstructs the five most relevant comparable deals, and gives BD teams and founders the frameworks they need to negotiate from data, not intuition.
Novartis just dropped $1.1B to acquire Myricx, adding another ADC asset to its oncology arsenal. The deal clears our Phase 2 oncology acquisition benchmarks on total value but raises questions about upfront structure. Here's what the numbers actually say — and what dealmakers should take away before their next term sheet.
The median upfront for a Phase 2 radiopharmaceutical gastroenterology acquisition now sits at $275M — but total deal values stretch past $3.3B when milestone stacks are fully loaded. Here's how the biggest GI radiopharmaceutical deals are actually structured, what the benchmark data reveals, and what you should demand at the table.
The median upfront for a Phase 2 peptide dermatology acquisition now sits at $275M, but total deal values stretch beyond $3.3B — a spread that reveals how acquirers are pricing clinical and commercial risk in one of pharma's most competitive therapeutic areas. Here's how the deal structures actually break down and what they mean for your next negotiation.
The median upfront for a Phase 2 CAR-T ophthalmology acquisition just crossed $120M — yet total deal values are stretching to $2.5B, revealing a massive conviction gap between what acquirers will pay now versus what they think these assets are worth. Here's how the deal math actually works, what recent ophthalmology acquisitions tell us about buyer psychology, and why the conventional playbook is wrong.
The median upfront for a Phase 2 PROTAC infectious disease acquisition is $275M — but total deal values stretch past $3.3B when milestones are stacked right. We break down exactly how these deals are structured, what the comparables tell you, and where the negotiation leverage actually sits.
The median upfront for a Phase 2 mRNA hematology acquisition now sits at $275M — but total deal values are stretching past $3B. We break down the benchmark data, deconstruct the biggest comparable deals, and deliver a negotiation playbook for both founders and BD professionals.
The median upfront for an RNAi rare disease acquisition at Phase 2 is $275M — but the spread between the floor and ceiling reveals a market that prices platform potential very differently from single-asset value. Here's what the benchmark data, comparable transactions, and deal structures actually tell sophisticated negotiators heading into 2025-2026 term sheets.
The median upfront for a Phase 2 cell therapy cardiovascular acquisition now sits at $275M — but total deal values routinely blow past $3B. We break down comparable deals, introduce the Regenerative Risk Premium framework, and give both founders and BD teams a negotiation playbook grounded in 2024-2025 transaction data.
The median upfront for a Phase 2 gene therapy metabolic acquisition now sits at $120M — but total deal values stretch to $2.5B, meaning acquirers are structuring 80%+ of consideration as contingent milestones. We break down what these structures actually mean for sellers and buyers.
The median upfront for a Phase 2 monoclonal antibody immunology acquisition now sits at $275M — but total deal values stretch past $3.3B. We break down the benchmark data, deconstruct the 2025 comps rewriting the playbook, and show you exactly where the leverage sits for both buyers and sellers.
The median upfront payment for a small molecule neurology acquisition at Phase 2 is $120M — but the real story is in the total deal values now routinely exceeding $1B. We break down five comparable transactions, introduce the Neuro Premium Multiplier framework, and deliver a negotiation playbook for both founders and BD teams.
The median upfront for a Phase 2 bispecific antibody oncology acquisition has hit $275M — and total deal values are routinely breaching $3B. We break down the five biggest comparable deals, introduce a framework for evaluating buyer conviction, and deliver a negotiation playbook for both founders and BD teams.
The median upfront for a Phase 2 radiopharmaceutical women's health acquisition now sits at $275M — but total deal values stretch beyond $3.3B, revealing a massive conviction gap between what buyers pay at signing and what they promise on the back end. Here's what the benchmark data, comparable transactions, and deal structures actually tell us about where this niche is heading.
The median upfront for a Phase 2 peptide gastroenterology acquisition is $120M, but total deal values are stretching past $2.5B as Big Pharma chases GI pipeline gaps. Here's exactly how these deals are structured, why the milestone-to-upfront ratios reveal buyer conviction, and what BD teams should demand at the table.
The median upfront for a Phase 2 CAR-T (hematologic) dermatology acquisition now sits at $275M — but total deal values stretch beyond $3.3B when milestones play out. We break down every lever, deconstruct the biggest comparable transactions, and hand you a negotiation playbook built for the current market.
The median upfront for a Phase 2 PROTAC ophthalmology acquisition now sits at $120M — but the spread between the floor and ceiling tells a far more important story. We break down the benchmarks, deconstruct the biggest comparable deals, and deliver a tactical playbook for founders and BD teams negotiating in this emerging sweet spot.
The median upfront for an mRNA infectious disease acquisition at Phase 2 is $275M — but total deal values routinely exceed $1B. We break down the benchmarks, deconstruct the biggest comps, and offer a tactical playbook for both sides of the table.
The median upfront for an RNAi hematology acquisition at Phase 2 is $275M — but total deal values are stretching past $3B. We break down the benchmark data, deconstruct the biggest recent deals, and lay out a negotiation playbook for both sides of the table.
The median upfront for a Phase 2 cell therapy rare disease acquisition now sits at $342.5M — a figure that would have been unthinkable five years ago. We break down the benchmark data, deconstruct the deals that set these precedents, and lay out what BD teams and founders should demand at the table.
The median upfront payment for a Phase 2 gene therapy cardiovascular acquisition now sits at $342.5M — a number that would have been unthinkable five years ago. We break down the benchmark data, deconstruct the biggest recent deals, and deliver a negotiation playbook for both biotech founders and pharma BD professionals.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.
Try Solidus
